2024
Synaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss
2000
Synthesis and evaluation of an 18F analog of forskolin for imaging adenylyl cyclase
Kiesewetter D, Sassaman M, Robbins J, Jagoda E, Carson R, Appel N, Sutkowski E, Herscovitch P, Braun A, Eckelman W. Synthesis and evaluation of an 18F analog of forskolin for imaging adenylyl cyclase. Journal Of Fluorine Chemistry 2000, 101: 297-304. DOI: 10.1016/s0022-1139(99)00174-8.Peer-Reviewed Original ResearchEffective imaging agentRapid deprotectionCarbamate analoguesAdenylyl cyclaseImaging agentPositron emission tomographyBrain uptakeSecond messenger systemsEmission tomographyDeprotectionLiving brainAnaloguesAminesAnalogue of forskolinFluorineMessenger systemsForskolinSynthesisCompoundsPotential agentCarbamateCyclase